General Information of the Drug (ID: M6APDG04337)
Name
MEDI-543
Synonyms
MEDI-EphA2; L/A Lm-MCMV vaccine, Cerus/MedImmune; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus; Listeria monocytogenes-based immunotherapy (EphA2-targeting), Cerus/MedImmune; Live-attenuated Listeria monocytogenes (Lm)-based vaccine (CMV), Cerus/MedImmune
    Click to Show/Hide
Status
Preclinical
TTD Drug ID
D0W8HP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ephrin type-A receptor 2 (EPHA2)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-543. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MEDI-543 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-543. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of MEDI-543 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-543. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEDI-543 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). [1], [2]
References
Ref 1 m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis. 2022 May 21;13(5):483. doi: 10.1038/s41419-022-04950-2.
Ref 2 Clinical pipeline report, company report or official report of Daiichi Sankyo.